Clonal architectures and driver mutations in metastatic melanomas.

Area of Science:

• Oncology
• Genomics
• Cancer Research

Background:

• Melanoma exhibits complex clonal architecture.
• Driver mutations are key to melanoma development and progression.

Purpose of the Study:

• To elucidate the clonal architecture and driver mutations in melanoma.
• To identify novel genes implicated in melanoma pathogenesis.
• To understand the genetic basis of drug resistance in metastatic melanoma.

Main Methods:

• Whole genome sequencing (WGS) and targeted extension sequencing were performed on 124 melanoma cases.
• Significantly mutated gene analysis identified known and novel melanoma genes.
• Deep sequencing revealed tumor subclones and analyzed mutation signatures.

Main Results:

• Identified known melanoma genes (BRAF, NRAS, CDKN2A) and a novel gene (EPHA3).
• Discovered numerous mutations in tumor suppressors, protein phosphatases, and chromatin remodeling genes.
• Found subclones in most metastatic tumors; 12/13 WGS patients showed a UV mutation signature, with one exception (MEL9) exhibiting distinct clonal signatures.

Conclusions:

• Clonal evaluation is essential for understanding melanoma etiology.
• Genetic alterations drive differential drug resistance in metastatic melanoma.
• Distinct mutational mechanisms can operate within different clones of the same tumor.